<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086408</url>
  </required_header>
  <id_info>
    <org_study_id>40295</org_study_id>
    <nct_id>NCT03086408</nct_id>
  </id_info>
  <brief_title>Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and Diagnostic Bronchoscopy</brief_title>
  <official_title>The Safety and Efficacy of the Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) for Short Diagnostic Bronchoscopy Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether diagnostic bronchoscopy can be safely and
      potentially more effectively performed without the use of tracheal intubation or a
      supraglottic airway, under completely unobstructed surgical conditions afforded by THRIVE:
      Transnasal Humidified Rapid- Insufflation Ventilatory Exchange. THRIVE provides patient's gas
      exchange through rapid insufflation of high-flow oxygen via specialized nasal cannula.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of THRIVE on oxygenation</measure>
    <time_frame>intraoperative</time_frame>
    <description>SpO2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of THRIVE on operating time</measure>
    <time_frame>intraoperative</time_frame>
    <description>surgical duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of THRIVE on recovery room stay</measure>
    <time_frame>1-2 hours after procedure</time_frame>
    <description>recovery room time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of THRIVE on postoperative recovery</measure>
    <time_frame>from recovery room stay to 7th day after surgery</time_frame>
    <description>consumption of analgesic drugs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bronchoscopy</condition>
  <arm_group>
    <arm_group_label>THRIVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high flow nasal oxygen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endotracheal tube or supraglottic airway</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tracheal intubation or supraglottic airway device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>THRIVE</intervention_name>
    <description>active nasal oxygen delivery system</description>
    <arm_group_label>THRIVE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tube or Supraglottic airway</intervention_name>
    <description>Plastic devices for mechanical ventilation</description>
    <arm_group_label>endotracheal tube or supraglottic airway</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting for diagnostic bronchoscopy

        Exclusion Criteria:

          -  Patients with significantly decreased myocardial function (ejection fraction &lt; 50%)

          -  Patients with abnormal cardiac rhythm and conduction abnormalities, except for
             patients with isolated, asymptomatic premature atrial and ventricular contractions.

          -  Patients with significant peripheral vascular disease, such as those with the symptoms
             of intermittent claudication.

          -  Patients with known significant cerebrovascular disease, such as history of
             cerebrovascular accidents (CVAs) and transient ischemic attacks (TIAs).

          -  Patients with significant renal insufficiency, as manifested by estimated glomerular
             filtration rate (eGFR) &lt; 60 ml/min/1.73 m2.

          -  Patients with electrolyte (K+, Ca++) abnormalities, as determined by the lab values
             outside of a normal range.

          -  Patients with the history or symptoms of increased intracranial pressure or reduced
             intracranial compliance (e.g. headaches, nausea and vomiting, visual changes, mental
             changes).

          -  Patients with skull base defects.

          -  Patients with pulmonary hypertension who have pulmonary artery pressures above the
             normal range.

          -  Patients with significant chronic obstructive or restrictive lung diseases, as
             manifested by known history of baseline chronic hypoxia and/or hypercapnia, and/or
             baseline room air SpO2 &lt; 95%.

          -  Obese patients with BMI above 35 kg/m2.

          -  Patients with severe and poorly controlled gastroesophageal reflux disease despite
             medical treatment.

          -  Patients with hiatal hernia and full stomach patients.

          -  Patients on immunosuppressive medications.

          -  Patient's refusal to participate in the study.

          -  Patients who do not understand English or mentally handicapped.

          -  Pregnant or breastfeeding patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrell M Wilson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladimir Nekhendzy</last_name>
    <phone>6504984055</phone>
    <email>nek@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Nekhendzy</last_name>
      <email>nek@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Vladimir Nekhendzy</investigator_full_name>
    <investigator_title>Clinical Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>airway management</keyword>
  <keyword>high flow nasal oxygen</keyword>
  <keyword>high flow nasal cannula</keyword>
  <keyword>THRIVE</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

